Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

Buying stocks is quick and straightforward once you have a brokerage account. Learn how with this step-by-step guide. Many, or all, of the products featured on this page are from our advertising ...

Trading options requires answering these questions: Which direction will a stock move, how far will it go and when will it happen? Here are 4 steps to get started. Many, or all, of the products ...